๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Wuhan
Clinical trial register · China

Clinical Trials in Wuhan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology165 Tongji Hospital139 Huazhong University of Science and Technology45 Novartis Pharmaceuticals33 AbbVie31
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Wuhan

1343 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
AbbVie
Phase 3
573
Hefei, Beijing, Chongqing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2025-06-17
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
Beijing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong, Wuxi
2025-06-13
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
NCT06951711Bipolar Disorder Type I With Mania or Mania With Mixed Features
Bristol-Myers Squibb
Phase 3
274
Beijing, Wuhan, Changsha, Jining Shi, Tianjin
2025-06-13
Recruiting
A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors
NCT06990698Advanced Solid Tumors
Zhuhai Fapon Biopharma Co., Ltd.
Phase 1
108
Wuhan, Taiyuan, Hangzhou
2025-06-12
Recruiting
Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors
NCT07301801Malignant Tumors, SSTR2, PET
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1
10
Wuhan
2025-06-12
Recruiting
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
NCT06931691Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals
Observational
80
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nantong, Nanchang, Changchun
2025-06-10
Recruiting
AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
NCT07062380Hepatecellular Carcinoma, Hepatectomy
Tongji Hospital
Observational
353
Wuhan
2025-06-10
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
NCT06808984Agitation, Alzheimer Disease
Celgene
Phase 2
120
Hefei, Beijing, Wuhan, Nanjing, Shanghai Shi, Hangzhou
2025-06-09
Recruiting
A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs
NCT07069569Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi, Wuhan, Changchun
2025-06-08
Recruiting
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125Dravet Syndrome
Stoke Therapeutics, Inc
Phase 3
170
Beijing, Guangzhou, Wuhan
2025-06-04
Recruiting
Protein A Immunoadsorption in Dilated Cardiomyopathy (RPIA-DCM)
NCT06922851Dilated Cardiomyopathy (DCM)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
60
Wuhan
2025-06-04
Recruiting
Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma
NCT07301827Renal Cell Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
66
Wuhan
2025-06-01
Recruiting
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
NCT07267117Heart Valve Disease, Mitral Valve (MV) Regurgitation, Mitral Valve Disease, Mitral Valve Stenosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Fuzhou, Wuhan, Changsha, Shenyang, Xi'an, Qingdao, Chengdu, รœrรผmqi
2025-06-01
Not yet open
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer
NCT06990503Ovarian Cancer
Tongji Hospital
Phase 3
300
Wuhan
2025-06-01
Not yet open
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer
NCT06990516Ovarian Cancer
Tongji Hospital
Phase 1/2
90
Wuhan
2025-06-01
Recruiting
Indomethacin vs Diclofenac for Preventing PEP
NCT07071441ERCP, Pancreatitis, Non-steroidal Anti-inflammatory (NSAID), Indomethacin
Air Force Military Medical University, China
Not applicable
4,050
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Jilin City
2025-06-01
Not yet open
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
NCT06961188Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity, Untreated With Systemic Therapy
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
174
Wuhan
2025-06-01
Not yet open
Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection
NCT06982547Rheumatoid Arthritis (RA)
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1
24
Wuhan
2025-06
Not yet open
Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.
NCT06982534Systemic Sclerosis (SSc)
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1
24
Wuhan
2025-06
Not yet open
An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus
NCT06945068Systemic Lupus Erythematosus (SLE)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
19
Wuhan
2025-06
Not yet open
Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
NCT07010588Hepatocellular Carcinoma (HCC), Magnetic Resonance Imaging (MRI), Randomized Controlled Trial
Peking University People's Hospital
Not applicable
1,389
Beijing, Chongqing, Handan, Harbin, Wuhan, Changchun, Jinan, Qingdao
2025-06
Recruiting
The Clinical Study on the Treatment of SSc With UTAA91 Injection.
NCT07000682Systemic Sclerosis (SSc)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1
24
Wuhan
2025-05-30
Recruiting
The Clinical Study on the Treatment of Refractory RA With UTAA91 Injection
NCT07001956Rheumatoid Arthritis (RA)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1
24
Wuhan
2025-05-30
Recruiting
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
NCT06954584Ovarian Cancer
Tongji Hospital
Phase 3
424
Wuhan
2025-05-27
Recruiting
Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
NCT06971094SMA - Spinal Muscular Atrophy
GeneCradle Inc
Phase 3
50
Beijing, Shanghai, Shenzhen, Suzhou, Wuhan
2025-05-27
Active, closed
Intelligent Accelerated MRI for Pediatric Abdominal Pain
NCT07164651Pediatric Abdominal Pain
Yaqi Shen๏ผŒMD๏ผŒPhD
Observational
150
Wuhan
2025-05-26
Active, closed
A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants
NCT07032597Mid Face Volume Deficit
AbbVie
Phase 3
252
Beijing, Wuhan, Nanjing, Wuxi, Shanghai, Hangzhou
2025-05-26
Recruiting
Treatment of Moyamoya Disease With iPSC-derived Exosomes
NCT07065409Moyamoya Disease
Huaqiu Zhang
Phase 1
9
Wuhan
2025-05-26
Active, closed
A Study for the Evaluation of Efficacy and Safety of Proliaยฎ in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
NCT06588153Glucocorticoid-induced Osteoporosis
Amgen
Phase 4
102
Beijing, Guangzhou, Shenzhen, Luoyang, Wuhan, Changzhou, Huaian, Nantong
2025-05-24
Recruiting
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
NCT07002112Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University
Phase 1
30
Hefei, Beijing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-05-23
Recruiting
Efficacy and Safety of Sanggua Tablets in the Treatment of Patients With Impaired Glucose Tolerance and Mild Type 2 Diabetes
NCT06964620Diabetes Mellitus, Type 2, Impaired Glucose Tolerance
Tongji Hospital
Phase EARLY_PHASE1
84
Wuhan
2025-05-22
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
500
Hefei, Fuzhou, Guangzhou, Harbin, Zhenngzhou, Wuhan, Xining, Shanghai
2025-05-22
Not yet open
A Study of Cetuximabฮฒ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer
NCT07000305Advanced Colorectal Cancer
Tao Zhang
Phase 2
42
Wuhan
2025-05-20
Recruiting
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
NCT06711887Lupus Nephritis
Novartis Pharmaceuticals
Phase 3
348
Guangzhou, Shantou, Shenzhen, Liuzhou, Wuhan, Changchun, Shenyang, Binzhou
2025-05-19
Recruiting
Goal Commitment and Proactive Health Behavior in Chronic Disease Patients
NCT07552571Hypertension, Diabetes Mellitus, Dyslipidemia
Xiong Juyang
Not applicable
600
Wuhan
2025-05-15
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,440
Beijing, Chongqing, Fuzhou, Guangzhou, Zhuhai, Nanning, Zhengzhou, Wuhan
2025-05-13
Active, closed
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
NCT06934044Multiple Myeloma
Hoffmann-La Roche
Phase 1
20
Guangzhou, Tianjin, Nanchang, Wenzhou, Wuhan
2025-05-13
Recruiting
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
NCT06749899Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Sun Yat-Sen University Cancer Center
Phase 3
580
Fuzhou, Dongguan, Foshan, Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan
2025-05-04
By invitation
School-EduSmoke: A Cluster Randomized Controlled Trial for Promoting Smoking Cessation Among Parents of Schoolchildren
NCT06853483Smoking Cessation
Huazhong University of Science and Technology
Not applicable
700
Wuhan
2025-05-03
Recruiting
A Longitudinal Cohort Study on the Changes of Physiological Mechanisms in Children After Biliary Tract Reconstruction
NCT07530354Choledochal Cyst
Wuhan Children's Hospital
Observational
100
Wuhan
2025-05-01
Not yet open
A Real-World Study of Neoadjuvant/Conversion Therapy for Colorectal Cancer With Chemotherapy And Anti-Angiogenic Targeted Agents
NCT06470178Colorectal Cancer
Wuhan University
Observational
70
Wuhan
2025-05-01
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT06916806Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
AstraZeneca
Phase 1
72
Beijing, Shanghai, Wuhan, Zhengzhou
2025-05-01
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
NCT06884618Neoplasms
Hoffmann-La Roche
Phase 1
405
Guangzhou, Shanghai, Wuhan
2025-04-30
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
Beijing, Chengdu, Shanghai, Wuhan
2025-04-29
Recruiting
The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
NCT06927310Idiopathic Short Stature
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
300
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Wuhan
2025-04-28
Recruiting
Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer
NCT06945523Advanced Lung Cancer
Chongqing Precision Biotech Co., Ltd
Phase 1
60
Wuhan
2025-04-28
Recruiting
A Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Severe Acute Respiratory Distress Syndrome
NCT07413978Acute Respiratory Distress Syndrome
Changchun Tuohua Pharmaceutical Co., Ltd.
Phase 1/2
36
Wuhan
2025-04-25
Recruiting
Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer
NCT06980532Metastatic Colorectal Cancer
Liu Huang
Phase 1/2
42
Wuhan
2025-04-25
Recruiting
The Application of an AI-driven Multimodal Predictive Model for Cognitive Impairment in Patients With Type 2 Diabetes Mellitus
NCT07128186Cognitive Dysfunction
Tongji Hospital
Observational
5,000
Enshi, Huanggang, Huangshi, Jingzhou, Shiyan, Suizhou, Wuhan, Xiangyang
2025-04-22
Recruiting
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
NCT07347171Leukemia, AML, MDS, AML (Acute Myelogenous Leukemia)
Cullgen (Shanghai),Inc
Phase 1
45
Nanchang, Tianjin, Wuhan
2025-04-17
Not yet open
(Withdrawal) AI-Based Low-Dose 3D-DSA Reconstruction
NCT06769867Cerebrovascular Disease
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
134
Wuhan
2025-04-15
Active, closed
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
NCT06900543Unresectable Hepatocellular Carcinoma
Chengdu New Radiomedicine Technology Co. LTD.
Phase 3
108
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Shenyang, Xiโ€™an, Chengdu
2025-04-15
Recruiting
Electrical Impedance Tomography-Based Prognostic Model for ARDS
NCT06967207Acute Respiratory Distress Syndrome (ARDS), Ventilator-induced Lung Injury
XiaoJing Zou,MD
Observational
625
Guangzhou, Wuhan, Shanghai
2025-04-15
Recruiting
Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases
NCT07092202Leptomeningeal Metastasis, NSCLC, Intrathecal Chemotherapy, Tyrosine Kinase Inhibitor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4
40
Wuhan
2025-04-15
Recruiting
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ยฑ Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
NCT06821503Advanced Pancreatic Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
72
Beijing, Chongqing, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Shenyang
2025-04-11
Recruiting
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
869
Bengbu, Beijing, Guangzhou, Liuzhou, Xingtai, Luoyang, Changsha, Wuhan
2025-04-09
Recruiting
Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes
NCT06861062Diabetes Mellitus, Type 2
Huazhong University of Science and Technology
Not applicable
2,500
Nanning, Tangshan, Shiyan, Wuhan, Chengdu
2025-04-08
Recruiting
Efficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial
NCT06883864Atrial Fibrillation (AF), Catheter Ablation, Atrial Functional Mitral Regurgitation
Beijing Anzhen Hospital
Not applicable
146
Hefei, Beijing, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2025-04-08
Recruiting
Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
NCT06902844Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Tongji Hospital
Not applicable
6
Wuhan
2025-04-05
Recruiting
A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals
NCT06932523Herpes Zoster (HZ)
Shanghai Institute Of Biological Products
Phase 1/2
645
Wuhan
2025-04-04
Recruiting
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
NCT06839066Nasopharyngeal Carcinoma (NPC)
Shanghai Henlius Biotech
Phase 2
70
Fuzhou, Dongguan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2025-04-02
Recruiting
Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5
NCT06901960Chronic Kidney Disease (Stages 3b-5)
Peking University First Hospital
Not applicable
1,066
Beijing, Nanning, Wuhan
2025-04-02
Recruiting
Using Artificial Intelligence to Improve Radiologists' Performance in Radiology Report Writing: a Randomised Controlled Trial
NCT06907927Healthy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
100
Wuhan
2025-04-01
Recruiting
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
NCT06867536Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoma
Liling Zhang
Phase 2
40
Wuhan
2025-04-01
Recruiting
To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease
NCT07149571Nonalcoholic Fatty Liver Disease, Metabolic-associated Fatty Liver Disease
Tongji Hospital
Observational
500
Wuhan
2025-04-01
Not yet open
Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
NCT06896396Unresectable Hepatocellular Carcinoma
Zhiyong Huang
Phase 1/2
60
Wuhan
2025-04-01
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi
Phase 3
300
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Wuhan
2025-04-01
Recruiting
Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma
NCT06825546Advanced Pancreatic Ductal Adenocarcinoma
Sir Run Run Shaw Hospital
Phase 2
70
Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou, Wenzhou
2025-04-01
Not yet open
Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Myeloid Malignancies
NCT06917105Myeloid Malignancies, CAR-T
Tongji Hospital
Phase 1/2
45
Wuhan
2025-04-01
Not yet open
Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy
NCT06916442PET/CT, Solid Tumors, Adult, Solid Tumors, Advanced Solid Tumors
Zhongnan Hospital
Observational
200
Wuhan
2025-04-01
Not yet open
A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer
NCT06464601Gastric Cancer
Wuhan University
Observational
70
Wuhan
2025-04-01
Recruiting
Application of Remimazolam, Dexmedetomidine, and Esketamine in Pediatric Preoperative Sedation
NCT07050212Remimazolam, Dexmedetomidine, Esketamine
Maternal and Child Health Hospital of Hubei Province
Not applicable
150
Wuhan
2025-04-01
Not yet open
A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
NCT06922929Prostate Cancer Recurrent
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
110
Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou
2025-04
Not yet open
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
NCT06922903Prostate Cancer
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3
240
Beijing, Cangzhou, Wuhan, Yichang, Changsha, Nanjing, Suzhou, Taizhou
2025-04
Recruiting
To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
NCT06833983Hemophilia A
Gritgen Therapeutics Co., Ltd.
Phase 3
50
Hefei, Beijing, Lanzhou, Guangzhou, Tangshan, Zhengzhou, Wuhan, Changsha
2025-03-31
Recruiting
High - Dose Vitamin C Infusion Regimen Based on Pharmacokinetic Characteristics for Patients With Advanced Malignant Solid Tumors
NCT07121036Vitamin C
Zhongnan Hospital
Phase 1
18
Wuhan
2025-03-30
Recruiting
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
NCT07152041Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
150
Hefei, Chongqing, Fuzhou, Guangzhou, Guiyang, Wuhan, Changsha, Nanjin
2025-03-28
Recruiting
The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
NCT06620809Neuromyelitis Optica Spectrum Disorders
Tongji Hospital
Phase 1
69
Wuhan
2025-03-28
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
NCT06867094Colitis Ulcerative
Sanofi
Phase 2
204
Guangzhou, Hangzhou, Huizhou, Jiazhuang, Linhai, Luoyang, Shanghai, Wuhan
2025-03-28
Recruiting
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
NCT06909474T-ALL/Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1
15
Wuhan
2025-03-27
Recruiting
Intraoperative Paravertebral Block and Postoperative Complications
NCT07211529Video-assisted Thoracoscopic Surgery (VATS), Lung Cancer (Diagnosis), Pulmonary Infections, Respiratory Failure Without Hypercapnia
Tongji Hospital
Not applicable
500
Wuhan
2025-03-25
Recruiting
Manual Acupuncture (MA) for Asymptomatic Hyperuricemia (HUA)
NCT06824376Asymptomatic Hyperuricemia
Shenghao Tu
Not applicable
260
Wuhan
2025-03-25
Recruiting
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
NCT06914128MTAP-deleted Solid Tumors
Bayer
Phase 1/2
450
Beijing, Wuhan, Nanjing, Hangzhou
2025-03-21
Recruiting
Effect of Adding Electroacupuncture to Anti-cancer Therapy-induced Peripheral Neuropathy
NCT06858709Chemotherapy-induced Peripheral Neuropathy (CIPN), Cancer
Zhongnan Hospital
Not applicable
150
Wuhan
2025-03-20
Recruiting
Phase II Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis
NCT07547735Knee Osteoarthritis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
100
Wuhan
2025-03-20
Active, closed
fMRI Study on Cerebral Localization and Network Mechanisms of rTMS in Chronic Ankle Instability Treatment
NCT06971705Chronic Ankle Instability, CAI, Functional Magnetic Resonance Imaging (fMRI)
Wuhan University
Not applicable
40
Wuhan
2025-03-20
Recruiting
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
NCT06840002Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
150
Wuhan
2025-03-18
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,000
Bengbu, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Wuhan, Xiangyang
2025-03-16
Active, closed
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048Neovascular Age-related Macular Degeneration (nAMD)
Hoffmann-La Roche
Phase 4
274
Beijing, Chengdu, Guangzhou, Shanghai, Wuhan
2025-03-14
Recruiting
A Study of SHR-A1811 in Subjects With Ovarian Cancer
NCT06828354Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
300
Wuhan, Jinan
2025-03-13
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
AstraZeneca
Phase 2
80
Beijing, Chengdu, Harbin, Shanghai, Wuhan, Zhengzhou
2025-03-12
Recruiting
Effect of Bone Augmentation Simultaneous to Implant Removal on the Prognosis of Reimplantation at the Same Site
NCT07078890Implant Failure, Bone Augmentation, Prognosis
The Dental Hospital of Zhejiang University School of Medicine
Not applicable
40
Wuhan, Hangzhou, Shanghai
2025-03-12
Recruiting
Newly-diagnosed Pediatric T-cell ALL Protocol
NCT06855810Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
610
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-11
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
Takeda
Phase 3
600
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Luoyang, Wuhan, Zhuzhou
2025-03-10
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
Alexion Pharmaceuticals, Inc.
Phase 2
47
Changsha, Guangzhou, Nanning, Shanghai, Wuhan, Xi'an
2025-03-07
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623Non Small Cell Lung Carcinoma
AbbVie
Phase 1/2
252
Beijing, Fuzhou, Liuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2025-03-06
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma
BeOne Medicines
Phase 3
300
Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Xuzhou
2025-03-05
Recruiting
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
NCT06882057Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
3,000
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-03
Not yet open
AI-based Low Dose CBCT Reconstruction for Clinical Application
NCT06831617Lung Nodule
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
400
Wuhan
2025-03-01
Recruiting
Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
NCT07088354Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy, Pathological Complete Response, Deep Learning
Tongji Hospital
Observational
300
Wuhan
2025-03-01
Rows per page Showing 501–600 of 1343
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/wuhan?page=6

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,343 of those studies with a site in Wuhan.

How many clinical trials are recruiting in Wuhan?

798 of the 1,343 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 226 have not yet opened recruitment, 281 are active but closed to new participants, and 38 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.